The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Ross Robert W. | Director | Grant(A) | 5K | — | $0 |
| Jun 11, 2026 | Bonstein Sara | Director | Grant(A) | 5K | — | $0 |
| Jun 11, 2026 | Brennan Aoife | Director | Grant(A) | 5K | — | $0 |
| Jun 11, 2026 | Bello Akintunde Olatokumbo | Director | Grant(A) | 5K | — | $0 |
| Jun 11, 2026 | Shannon James Samuel | Director | Grant(A) | 5K | — | $0 |
| Jun 11, 2026 | Curran Daniel J. | Director | Grant(A) | 5K | — | $0 |
| Jun 11, 2026 | Xu Yuan | Director | Grant(A) | 5K | — | $0 |
| Mar 26, 2026 | Shannon James Samuel | Director | Buy(P) | 5K | $8.79 | $44K |
| Feb 13, 2026 | Gilead Sciences, Inc. | 10% Owner | Buy(P) | 3.7M | $0.53 | $2.0M |
| Jan 2, 2026 | Frankenfield Christopher James | Chief Financial Officer | Sell(S) | 7K | $0.64 | $4K |
| Jan 2, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Sell(S) | 2K | $0.64 | $1K |
| Jan 1, 2026 | Russo Rene | PRESIDENT AND CEO, Director | Option exercise(M) | 44K | — | — |
| Jan 1, 2026 | Russo Rene | PRESIDENT AND CEO, Director | Option exercise(M) | 44K | — | $0 |
| Jan 1, 2026 | Frankenfield Christopher James | Chief Financial Officer | Option exercise(M) | 19K | — | — |
| Jan 1, 2026 | Frankenfield Christopher James | Chief Financial Officer | Option exercise(M) | 19K | — | $0 |
| Jan 1, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Option exercise(M) | 5K | — | — |
| Jan 1, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Option exercise(M) | 5K | — | $0 |
| Jan 1, 2026 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Option exercise(M) | 17K | — | — |
| Jan 1, 2026 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Option exercise(M) | 17K | — | $0 |
| Dec 31, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 1.5M | — | $0 |
| Dec 31, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 669K | — | $0 |
| Dec 31, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant(A) | 95K | — | $0 |
| Dec 31, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant(A) | 452K | — | $0 |
| Nov 26, 2025 | Gilead Sciences, Inc. | 10% Owner | Option exercise(X) | 13.3M | — | $0 |
| Nov 26, 2025 | Gilead Sciences, Inc. | 10% Owner | Option exercise(X) | 13.3M | $0.75 | $10.0M |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 150K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 350K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 473K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 240K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 240K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 2.1M | — | $0 |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 473K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 135K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 135K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 50K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 50K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 100K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 100K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 350K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 700K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Disposed to issuer(D) | 700K | — | — |
| Nov 21, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 150K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 45K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 24K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 24K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 155K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 155K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 925K | — | $0 |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 300K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 300K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 150K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 150K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 117K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 117K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 20K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 20K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 45K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Disposed to issuer(D) | 37K | — | — |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 37K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant(A) | 106K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant(A) | 44K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Disposed to issuer(D) | 44K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant(A) | 625K | — | $0 |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Disposed to issuer(D) | 106K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Disposed to issuer(D) | 15K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Disposed to issuer(D) | 25K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant(A) | 35K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Disposed to issuer(D) | 35K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant(A) | 15K | — | — |
| Nov 21, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant(A) | 25K | — | — |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant(A) | 132K | — | $0 |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Disposed to issuer(D) | 55K | — | — |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant(A) | 55K | — | — |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Disposed to issuer(D) | 25K | — | — |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant(A) | 25K | — | — |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Disposed to issuer(D) | 20K | — | — |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant(A) | 20K | — | — |
| Jun 17, 2025 | Shannon James Samuel | Director | Buy(P) | 25K | $0.69 | $17K |
| Jun 16, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Buy(P) | 36K | $0.68 | $25K |
| Jun 16, 2025 | Shannon James Samuel | Director | Buy(P) | 45K | $0.69 | $31K |
| Jun 11, 2025 | Rossi Christina | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Shannon James Samuel | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Xu Yuan | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Clancy Paul J | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Curran Daniel J. | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Bonstein Sara | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Brennan Aoife | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Ross Robert W. | Director | Grant(A) | 31K | — | $0 |
| Jun 10, 2025 | Bello Akintunde Olatokumbo | Director | Grant(A) | 62K | — | $0 |
| Jun 5, 2025 | Gilead Sciences, Inc. | 10% Owner | Buy(P) | 13.3M | — | — |
| Jun 5, 2025 | Gilead Sciences, Inc. | 10% Owner | Buy(P) | 13.3M | — | — |
| Jun 5, 2025 | Gilead Sciences, Inc. | 10% Owner | Buy(P) | 13.3M | — | — |
| Jun 5, 2025 | Gilead Sciences, Inc. | 10% Owner | Buy(P) | 13.3M | — | — |
| Apr 15, 2025 | Frankenfield Christopher James | Chief Financial Officer | Grant(A) | 75K | — | $0 |
| Apr 15, 2025 | Russo Rene | PRESIDENT AND CEO, Director | Grant(A) | 190K | — | $0 |
| Jan 2, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Sell(S) | 2K | $0.98 | $2K |
| Jan 2, 2025 | Frankenfield Christopher James | Chief Financial Officer | Sell(S) | 7K | $0.98 | $7K |
| Jan 1, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Option exercise(M) | 5K | — | — |
| Jan 1, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Option exercise(M) | 5K | — | $0 |
| Jan 1, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant(A) | 60K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).